文献速递乳腺癌

英格兰乳腺癌筛查未参加者第二次定时预约的效果:一项随机对照试验

Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2017-05-15

该开放随机对照试验在英格兰六个NHS乳腺癌筛查中心纳入26 054名未参加首次预约的50-70岁女性,1:1随机分为第二次固定日期和时间预约组与电话预约对照组。结果显示干预组90天内参与率显著高于对照组(22% vs 12%),相对风险1.81(95%CI 1.70-1.93;p<0.0001)。

要点

  • 对未参加首次乳腺癌筛查预约的女性,发送第二次固定日期和时间的预约邀请可提高参与率。
  • 干预组90天内参与率为22%(2861/12807),对照组为12%(1632/13247),相对风险1.81(95%CI 1.70-1.93;p<0.0001)。
  • 该策略易于在筛查机构实施,若结合简单干预可能进一步提高参与率。

核心结论

  • 对乳腺癌筛查未参加者实施第二次固定日期和时间的预约政策可有效提高参与率。
  • 该策略易于在筛查机构实施,若结合简单干预可能进一步提高参与率并确保全国参与率趋势向上。
  • 该政策是否应随距离上次筛查时间而变化将需考虑。

研究设计与样本

  • 开放随机对照试验,在英格兰NHS乳腺癌筛查项目六个中心进行,按SX编号1:1随机分组。
  • 纳入50-70岁未参加首次预约的女性,共26 054名(干预组12 807名,对照组13 247名)。
  • 干预组收到固定日期和时间的第二次预约邀请,对照组收到含电话号码的邀请信以预约新筛查时间。
  • 主要终点为首次预约日期后90天内的参与率,采用泊松回归比较两组参与比例,按意向性治疗分析。

主要发现

  • 干预组90天内参与率为22%(2861/12 807),对照组为12%(1632/13 247),相对风险1.81(95%CI 1.70-1.93;p<0.0001)。

临床怎么用

  • 原文结论认为第二次固定日期和时间的预约政策可有效提高参与率,该策略易于在筛查机构实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In England, participation in breast cancer screening has been decreasing in the past 10 years, approaching the national minimum standard of 70%. Interventions aimed at improving participation need to be investigated and put into practice to stop this downward trend. We assessed the effect on participation of sending invitations for breast screening with a timed appointment to women who did not attend their first offered appointment within the NHS Breast Screening Programme (NHSBSP). METHODS: In this open, randomised controlled trial, women in six centres in the NHSBSP in England who were invited for routine breast cancer screening were randomly assigned (1:1) to receive an invitation to a second appointment with fixed date and time (intervention) or an invitation letter with a telephone number to call to book their new screening appointment (control) in the event of non-attendance at the first offered appointment. Randomisation was by SX number, a sequential unique identifier of each woman within the NHSBSP, and at the beginning of the study a coin toss decided whether women with odd or even SX numbers would be allocated to the intervention group. Women aged 50-70 years who did not attend their first offered appointment were eligible for the analysis. The primary endpoint was participation (ie, attendance at breast cancer screening) within 90 days of the date of the first offered appointment; we used Poisson regression to compare the proportion of women who participated in screening in the study groups. All analyses were by intention to treat. This trial is registered with Barts Health, number 009304QM. FINDINGS: We obtained 33 146 records of women invited for breast cancer screening at the six centres between June 2, 2014, and Sept 30, 2015, who did not attend their first offered appointment. 26 054 women were eligible for this analysis (12 807 in the intervention group and 13 247 in the control group). Participation within 90 days of the first offered appointment was significantly higher in the intervention group (2861 [22%] of 12 807) than in the control group (1632 [12%] of 13 247); relative risk of participation 1·81 (95% CI 1·70-1·93; p<0·0001). INTERPRETATION: These findings show that a policy of second appointments with fixed date and time for non-attenders of breast screening is effective in improving participation. This strategy can be easily implemented by the screening sites and, if combined with simple interventions, could further increase participation and ensure an upward shift in the participation trend nationally. Whether the policy should vary by time since last attended screen will have to be considered. FUNDING: National Health Service Cancer Screening Programmes and Department of Health Policy Research Programme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Allgood PC, Maroni R, Hudson S, et al. Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial. Lancet Oncol. 2017. PMID: 28522311. doi:10.1016/S1470-2045(17)30340-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。